Although several studies have indicated that selected biomarkers (such as tumor PD-L1 expression or the presence of CD8 + infiltrating lymphocytes) are correlated with patient response, there is still a need for other ancillary and non-invasive biomarkers that can be used to monitor response to ultimately help guide the treatment course. Here, CD274 is linked to neoplasm.